Patents by Inventor Steffen Walter

Steffen Walter has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Immunotherapy against several tumors including gastrointestinal and gastric cancer
    Patent number: 10933118
    Abstract: A pharmaceutical composition contains an antibody or a fragment thereof specific for COL6A3 for the treatment of a cancer. A method of treating a cancer includes administering to a subject in need thereof the pharmaceutical composition. A kit includes a container that contains the pharmaceutical composition. A method of producing an antibody or a fragment thereof against a peptide or a MHC/peptide complex. A method for detecting a diseased tissue includes administering to a subject in need thereof an antibody or a fragment thereof conjugated to a radioisotope and detecting a signal from the radioisotope in the subject. A method for treating a diseased tissue includes administering to a subject in need thereof an antibody or a fragment thereof conjugated to a toxin.
    Type: Grant
    Filed: June 5, 2020
    Date of Patent: March 2, 2021
    Assignee: Immatics Biotechnologies GmbH
    Inventors: Jens Fritsche, Toni Weinschenk, Steffen Walter, Peter Lewandrowski, Harpreet Singh
  • Immunotherapy against several tumors including neuronal and brain tumors
    Patent number: 10919931
    Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to 30 peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
    Type: Grant
    Filed: August 2, 2016
    Date of Patent: February 16, 2021
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Toni Weinschenk, Oliver Schoor, Claudia Trautwein, Norbert Hilf, Steffen Walter, Harpreet Singh
  • METHODS FOR MANUFACTURING T CELLS
    Publication number: 20210030803
    Abstract: The disclosure relates to methods of manufacturing T cells for adoptive immunotherapy. The disclosure further provides for methods of genetically transducing T cells, methods of using T cells, and T cell populations thereof. In an aspect, the disclosure provides for methods of thawing frozen peripheral blood mononuclear cells (PBMC), resting the thawed PBMC, activating the T cell in the cultured PBMC with an anti-CD3 antibody and an anti-CD28 antibody immobilized on a solid phase, transducing the activated T cell with a viral vector, expanding the transduced T cell, and obtaining expanded T cells.
    Type: Application
    Filed: October 2, 2020
    Publication date: February 4, 2021
    Inventors: Mamta KALRA, Zoe Coughlin, Amir Alpert, Steffen Walter, Ali Mohamed, Agathe Bourgogne
  • Immunotherapy against several tumors including neuronal and brain tumors
    Patent number: 10906936
    Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to 30 peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
    Type: Grant
    Filed: August 2, 2016
    Date of Patent: February 2, 2021
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Toni Weinschenk, Oliver Schoor, Claudia Trautwein, Norbert Hilf, Steffen Walter, Harpreet Singh
  • Immunotherapy against several tumors including gastrointestinal and gastric cancer
    Patent number: 10905741
    Abstract: A pharmaceutical composition contains an antibody or a fragment thereof specific for COL6A3 for the treatment of a cancer. A method of treating a cancer includes administering to a subject in need thereof the pharmaceutical composition. A kit includes a container that contains the pharmaceutical composition. A method of producing an antibody or a fragment thereof against a peptide or a MHC/peptide complex. A method for detecting a diseased tissue includes administering to a subject in need thereof an antibody or a fragment thereof conjugated to a radioisotope and detecting a signal from the radioisotope in the subject. A method for treating a diseased tissue includes administering to a subject in need thereof an antibody or a fragment thereof conjugated to a toxin.
    Type: Grant
    Filed: December 13, 2019
    Date of Patent: February 2, 2021
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Jens Fritsche, Toni Weinschenk, Steffen Walter, Peter Lewandrowski, Harpreet Singh
  • BATTERY FOR AN AT LEAST PARTIALLY ELECTRICALLY OPERATED/DRIVEN FUNCTIONAL DEVICE AND FUNCTIONAL DEVICE
    Publication number: 20210028412
    Abstract: A battery for an at least partially electrically operated functional device, including at least one battery cell module, in each of which a predetermined number of battery cells is clamped by a mechanical clamping device to form a cell stack. The clamping device transmits a traction force or a contact pressure corresponding to the traction force to the cell stack by delimiting elements and traction elements. A frame element is arranged in each case between at least two or some or each of the battery cells and/or the respective terminal battery cell and the delimiting element is arranged adjacent to the respective terminal battery cell and associated with it. The frame element includes a circumferential part and a free volume delimited by the circumferential part.
    Type: Application
    Filed: July 22, 2020
    Publication date: January 28, 2021
    Applicant: AUDI AG
    Inventors: Christian Gert VOIGT, Christoph GLASSL, Florian SCHELS, Dirk HOEFNER, Steffen WALTER, Michael BAYER, Tamas GYULAI, Waldemar BAUER
  • Immunotherapy against several tumors including gastrointestinal and gastric cancer
    Patent number: 10898546
    Abstract: A pharmaceutical composition contains an antibody or a fragment thereof specific for COL6A3 for the treatment of a cancer. A method of treating a cancer includes administering to a subject in need thereof the pharmaceutical composition. A kit includes a container that contains the pharmaceutical composition. A method of producing an antibody or a fragment thereof against a peptide or a MHC/peptide complex. A method for detecting a diseased tissue includes administering to a subject in need thereof an antibody or a fragment thereof conjugated to a radioisotope and detecting a signal from the radioisotope in the subject. A method for treating a diseased tissue includes administering to a subject in need thereof an antibody or a fragment thereof conjugated to a toxin.
    Type: Grant
    Filed: June 5, 2020
    Date of Patent: January 26, 2021
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Jens Fritsche, Toni Weinschenk, Steffen Walter, Peter Lewandrowski, Harpreet Singh
  • NOVEL T CELL RECEPTORS AND IMMUNE THERAPY USING THE SAME
    Publication number: 20200385468
    Abstract: The present invention pertains to antigen recognizing constructs against COL6A3 antigens. The invention in particular provides novel T cell receptor (TCR) based molecules which are selective and specific for the tumor expressed antigen COL6A3. The TCR of the invention, and COL6A3 antigen binding fragments derived therefrom, are of use for the diagnosis, treatment and prevention of COL6A3 expressing cancerous diseases. Further provided are nucleic acids encoding the antigen recognizing constructs of the invention, vectors comprising these nucleic acids, recombinant cells expressing the antigen recognizing constructs and pharmaceutical compositions comprising the compounds of the invention.
    Type: Application
    Filed: August 21, 2020
    Publication date: December 10, 2020
    Inventors: Leonie ALTEN, Dominik Maurer, Steffen Walter, Sebastian Bunk
  • OPTICAL MONITORING DEVICE
    Publication number: 20200384958
    Abstract: An optical monitoring system serves to monitor surroundings, having a monitoring apparatus, the visual or scanning field of which is captured by a lens, and a protection panel (112) which protects the lens from precipitation and covers at least the visual or scanning field of the monitoring apparatus. In order to avoid the signal quality of the monitoring apparatus being impaired by precipitation on the protection panel, it is proposed that the protection panel (12; 112; 218; 318) is acoustically coupled to at least one ultrasonic transducer (10). The optical monitoring system can be included into the control system of a vehicle for autonomous driving, wherein, overall, it is possible to obtain increased safety of the control system.
    Type: Application
    Filed: September 14, 2018
    Publication date: December 10, 2020
    Applicant: EchoVista GmbH
    Inventors: Lars NAJORKA, Steffen WALTER, Ole Gustav JOHANNESSEN, Oliver Simon MATTHEWS, Mincheol SHIN
  • NOVEL IMMUNOTHERAPY AGAINST NEURONAL AND BRAIN TUMORS
    Publication number: 20200345777
    Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to 11 novel peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
    Type: Application
    Filed: June 3, 2020
    Publication date: November 5, 2020
    Inventors: Toni WEINSCHENK, Oliver SCHOOR, Claudia TRAUTWEIN, Norbert HILF, Steffen WALTER, Harpreet SINGH
  • CLAMPING DEVICE FOR A BATTERY MODULE, BATTERY MODULE, AND MOTOR VEHICLE
    Publication number: 20200343498
    Abstract: The invention relates to a clamping device for clamping a cell stack having multiple battery cells disposed next to each other in a stacking direction (x), wherein the clamping device comprises at least one fastening element for fastening the clamping device to a battery housing, and first and second end plate units, wherein at least the first end plate unit includes an end plate which is firmly connected to the at least one fastening element and a deformation plate. The deformation plate is configured such that the deformation plate can be deformed by a deformation force (F) applied to the deformation plate in the case of a cell stack received in the clamping device when at least one battery cell of the cell stack swells.
    Type: Application
    Filed: April 17, 2020
    Publication date: October 29, 2020
    Applicant: AUDI AG
    Inventors: Martin SCHUESSLER, Steffen WALTER, Dirk HÖFNER
  • NOVEL IMMUNOTHERAPY AGAINST SEVERAL TUMORS INCLUDING GASTROINTESTINAL AND GASTRIC CANCER
    Publication number: 20200330552
    Abstract: A pharmaceutical composition contains an antibody or a fragment thereof specific for COL6A3 for the treatment of a cancer. A method of treating a cancer includes administering to a subject in need thereof the pharmaceutical composition. A kit includes a container that contains the pharmaceutical composition. A method of producing an antibody or a fragment thereof against a peptide or a MHC/peptide complex. A method for detecting a diseased tissue includes administering to a subject in need thereof an antibody or a fragment thereof conjugated to a radioisotope and detecting a signal from the radioisotope in the subject. A method for treating a diseased tissue includes administering to a subject in need thereof an antibody or a fragment thereof conjugated to a toxin.
    Type: Application
    Filed: June 5, 2020
    Publication date: October 22, 2020
    Inventors: Jens FRITSCHE, Toni WEINSCHENK, Steffen WALTER, Peter LEWANDROWSKI, Harpreet SINGH
  • T cell receptors and immune therapy using the same
    Patent number: 10800845
    Abstract: The present invention pertains to antigen recognizing constructs against COL6A3 antigens. The invention in particular provides novel T cell receptor (TCR) based molecules which are selective and specific for the tumor expressed antigen COL6A3. The TCR of the invention, and COL6A3 antigen binding fragments derived therefrom, are of use for the diagnosis, treatment and prevention of COL6A3 expressing cancerous diseases. Further provided are nucleic acids encoding the antigen recognizing constructs of the invention, vectors comprising these nucleic acids, recombinant cells expressing the antigen recognizing constructs and pharmaceutical compositions comprising the compounds of the invention.
    Type: Grant
    Filed: May 3, 2019
    Date of Patent: October 13, 2020
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Leonie Alten, Dominik Maurer, Steffen Walter, Sebastian Bunk
  • Immunotherapy against several tumors, such as lung cancer, including NSCLC
    Patent number: 10793602
    Abstract: A method of treating a patient who has glioblastoma and/or gastric cancer includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has glioblastoma and/or gastric cancer. A method of treating a patient who has glioblastoma and/or gastric cancer includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the glioblastoma and/or gastric cancer.
    Type: Grant
    Filed: September 25, 2019
    Date of Patent: October 6, 2020
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Toni Weinschenk, Steffen Walter, Jens Fritsche, Colette Song, Harpreet Singh
  • NOVEL IMMUNOTHERAPY AGAINST SEVERAL TUMORS INCLUDING GASTROINTESTINAL AND GASTRIC CANCER
    Publication number: 20200297801
    Abstract: A pharmaceutical composition contains an antibody or a fragment thereof specific for COL6A3 for the treatment of a cancer. A method of treating a cancer includes administering to a subject in need thereof the pharmaceutical composition. A kit includes a container that contains the pharmaceutical composition. A method of producing an antibody or a fragment thereof against a peptide or a MHC/peptide complex. A method for detecting a diseased tissue includes administering to a subject in need thereof an antibody or a fragment thereof conjugated to a radioisotope and detecting a signal from the radioisotope in the subject. A method for treating a diseased tissue includes administering to a subject in need thereof an antibody or a fragment thereof conjugated to a toxin.
    Type: Application
    Filed: June 5, 2020
    Publication date: September 24, 2020
    Inventors: Jens FRITSCHE, Toni WEINSCHENK, Steffen WALTER, Peter LEWANDROWSKI, Harpreet SINGH
  • Immunotherapy against neuronal and brain tumors
    Patent number: 10709735
    Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to 11 novel peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
    Type: Grant
    Filed: July 10, 2019
    Date of Patent: July 14, 2020
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Toni Weinschenk, Oliver Schoor, Claudia Trautwein, Norbert Hilf, Steffen Walter, Harpreet Singh
  • NOVEL IMMUNOTHERAPY AGAINST SEVERAL TUMORS INCLUDING GASTROINTESTINAL AND GASTRIC CANCER
    Publication number: 20200155645
    Abstract: A pharmaceutical composition contains an antibody or a fragment thereof specific for COL6A3 for the treatment of a cancer. A method of treating a cancer includes administering to a subject in need thereof the pharmaceutical composition. A kit includes a container that contains the pharmaceutical composition. A method of producing an antibody or a fragment thereof against a peptide or a MHC/peptide complex. A method for detecting a diseased tissue includes administering to a subject in need thereof an antibody or a fragment thereof conjugated to a radioisotope and detecting a signal from the radioisotope in the subject. A method for treating a diseased tissue includes administering to a subject in need thereof an antibody or a fragment thereof conjugated to a toxin.
    Type: Application
    Filed: December 13, 2019
    Publication date: May 21, 2020
    Inventors: Jens FRITSCHE, Toni WEINSCHENK, Steffen WALTER, Peter LEWANDROWSKI, Harpreet SINGH
  • METHOD FOR ARRANGING AT LEAST ONE PART OF A BATTERY HOUSING AND ARRANGEMENT DEVICE
    Publication number: 20200099017
    Abstract: A method for arranging at least one battery module and at least one part of a battery housing having a cooling device, which is arranged on a side of the part of the battery housing and which has a predetermined module placement area. In doing so, a thermally conductive component is placed on the cooling device, at least in the predetermined module placement area, and the at least one battery module is inserted in the module placement area and pressed against the thermally conductive component in a pressing direction (R) extending in the direction of the cooling device. Before the pressing, a counter-holder device is arranged on the cooling device, which supports the cooling device during pressing of the at least one battery module in the predetermined module placement area, opposite the pressing direction (R).
    Type: Application
    Filed: August 26, 2019
    Publication date: March 26, 2020
    Applicant: AUDI AG
    Inventors: Martin SCHUESSLER, Steffen WALTER
  • T cell receptors and immune therapy using the same
    Patent number: 10550182
    Abstract: The present invention pertains to antigen recognizing constructs against COL6A3 antigens. The invention in particular provides novel T cell receptor (TCR) based molecules which are selective and specific for the tumor expressed antigen COL6A3. The TCR of the invention, and COL6A3 antigen binding fragments derived therefrom, are of use for the diagnosis, treatment and prevention of COL6A3 expressing cancerous diseases. Further provided are nucleic acids encoding the antigen recognizing constructs of the invention, vectors comprising these nucleic acids, recombinant cells expressing the antigen recognizing constructs and pharmaceutical compositions comprising the compounds of the invention.
    Type: Grant
    Filed: August 15, 2017
    Date of Patent: February 4, 2020
    Assignee: Immatics Biotechnologies GmbH
    Inventors: Leonie Alten, Dominik Maurer, Steffen Walter, Sebastian Bunk
  • IMMUNOTHERAPY AGAINST SEVERAL TUMORS, SUCH AS LUNG CANCER, INCLUDING NSCLC
    Publication number: 20200031870
    Abstract: A method of treating a patient who has glioblastoma and/or gastric cancer includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has glioblastoma and/or gastric cancer. A method of treating a patient who has glioblastoma and/or gastric cancer includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the glioblastoma and/or gastric cancer.
    Type: Application
    Filed: October 11, 2019
    Publication date: January 30, 2020
    Inventors: Toni WEINSCHENK, Steffen WALTER, Jens FRITSCHE, Colette SONG, Harpreet SINGH